Cláudio Correia L C, Neubauer C, Azevedo A, Ribeiro F, Braga J, Carlos Passos L, Teixeira M, Matos M, Aires V, Souza V
Hospital Português-Salvador.
Arq Bras Cardiol. 1995 Dec;65(6):475-8.
To evaluate the clinical efficacy and safety of subcutaneous (SC) low molecular weight heparin (LMWH) compared to intravenous (IV) non fractioned heparin (NFH) in unstable angina, acute myocardial infarction and post-percutaneous transluminal coronary angioplasty.
From September/92 to April/94, 314 patients were randomized in two groups. Group I-- 154 patients treated with SC LMWH, using in the 1st phase SC LMWH with a dosage of 160 UaXa IC/kg/day (group IA--92 patients), and in the 2nd, a dosage of 320 UaXa IC/kg/day (group IB--62 patients). Group II--160 patients treated with IV NFH 100UI/kg (bolus), followed by 1000UI/h with adjusted dosage by activated partial thromboplastin time.
There was not a statistically significant difference among the three groups in relation to cardiac events, hemorrhagic complications and deaths.
The clinical efficacy and safety of SC LMWH in patients with unstable angina, acute myocardial infarction and post-percutaneous transluminal coronary angioplasty were similar to IV NFH with the dosages used in this study.
评估皮下注射低分子量肝素（LMWH）与静脉注射普通肝素（NFH）相比，在不稳定型心绞痛、急性心肌梗死及经皮腔内冠状动脉成形术后的临床疗效和安全性。
从1992年9月至1994年4月，314例患者被随机分为两组。第一组——154例患者接受皮下注射低分子量肝素治疗，在第一阶段皮下注射低分子量肝素，剂量为160抗Xa国际单位/公斤/天（IA组——92例患者），在第二阶段，剂量为320抗Xa国际单位/公斤/天（IB组——62例患者）。第二组——160例患者接受静脉注射普通肝素治疗，100单位/公斤（推注），随后以1000单位/小时持续静脉滴注，并根据活化部分凝血活酶时间调整剂量。
三组在心脏事件、出血并发症和死亡方面无统计学显著差异。
在本研究使用的剂量下，皮下注射低分子量肝素在不稳定型心绞痛、急性心肌梗死及经皮腔内冠状动脉成形术后患者中的临床疗效和安全性与静脉注射普通肝素相似。
